Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
Buy Beam Therapeutics For 2023
05:49am, Friday, 02'nd Dec 2022
Shares of Beam Therapeutics lost buying momentum in recent weeks. Gene-editing therapy stocks are out of favor.
Beam Therapeutics to Participate in Upcoming Investor Conferences
06:30am, Wednesday, 09'th Nov 2022
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man
Why Beam Therapeutics Stock Is Falling Today
12:17pm, Monday, 07'th Nov 2022
Beam's decision not to move forward with sickle cell treatment BEAM-102 isn't sitting well with investors today.
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Tops Revenue Estimates
09:03am, Monday, 07'th Nov 2022
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -20% and 51.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
10:14am, Thursday, 20'th Oct 2022
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR St
Beam Therapeutics: Now Is Not The Right Time To Own
06:38pm, Thursday, 15'th Sep 2022
Today, we put mid-cap biotech concern Beam Therapeutics Inc. in the spotlight for the first time. Beam Therapeutics is advancing its pipeline on a wide front and the stock has had a nice ride over the
Why Beam Therapeutics Stock Rocketed Higher This Week
09:25am, Friday, 26'th Aug 2022
The biotech's share price has been on a wild ride in 2022.
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
01:34pm, Monday, 22'nd Aug 2022
This article is excerpted from Tom Yeung's Profit & Protection newsletter dated Aug. 16, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.
A Comprehensive Guide to Genomic ETFs
12:03pm, Friday, 12'th Aug 2022
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates
09:02am, Tuesday, 09'th Aug 2022
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 5.56% and 26.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
05:08pm, Wednesday, 03'rd Aug 2022
Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted t
Why Beam Therapeutics Stock Dipped Today
01:38pm, Monday, 01'st Aug 2022
A clinical hold is weighing on the biotech's shares today.
Beam Therapeutics (BEAM) Stock Drops 4% on Clinical Hold News
10:36am, Monday, 01'st Aug 2022
Source: Natali_ Mis/ShutterStock.com Beam Therapeutics (NASDAQ: BEAM ) stock is slipping on Monday after the U.S. Food and Drug Administration (FDA) placed a clinical hold on one of its drugs. Accordi
FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collapses
09:31am, Monday, 01'st Aug 2022
The Food and Drug Administration placed a cancer study from Beam Therapeutics on hold Monday, leading Beam stock to topple. The post FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collap
Beam In On The ARKK Buffet
10:44pm, Sunday, 17'th Jul 2022
Cathie Wood's ARK Innovation ETF is one of the most controversial and followed ETFs. What if you cherry-picked her best ideas.
